thiotepa and Central Nervous System Neoplasm studies

Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).

Research Excerpts

Excerpt	Relevance	Reference
"Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age."	9.16	Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012)
"The combination of high doses of methotrexate (MTX) and cytarabine (araC) is the standard chemotherapy for patients with primary CNS lymphoma (PCNSL)."	9.15	Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. ( Corazzelli, G; Fava, S; Ferreri, AJ; Foppoli, M; Franzin, A; Licata, G; Paolini, R; Politi, LS; Ponzoni, M; Reni, M; Stelitano, C; Zaja, F; Zucca, E, 2011)
"We investigated the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiation therapy (WBRT) in patients with newly diagnosed primary central nervous system lymphoma."	9.12	Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol ( Al-Ali, HK; Dölken, G; Haas, A; Helke, K; Herbst, R; Hirt, C; Kiefer, T; Krüger, WH; Lotze, C; Montemurro, M; Niederwieser, D; Schüler, F; Schwenke, M; Theilig, A; Wolf, HH, 2007)
"Thiotepa-based conditioning followed by HSCT may be effective in most CNS lymphoma patients, with a manageable toxicity profile."	8.90	Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma. ( Bredeson, C; Fergusson, D; Kokolo, MB; O'Neill, J; Stewart, D; Tay, J; Tinmouth, AT, 2014)
"A retrospective analysis was performed of 48 consecutive patients who had undergone HDC/ASCT with TBC (thiotepa, busulfan, cyclophosphamide) conditioning for PCNSL (27 patients), secondary CNS lymphoma (SCNSL) (8 patients), or relapsed disease with CNS involvement (13 patients) from July 2006 to December 2017."	7.96	Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. ( Chute, J; de Vos, S; Eradat, HA; Gaut, D; Grotts, J; Kimaiyo, DK; Romero, T; Schiller, G; Timmerman, J; Young, PA, 2020)
"We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) and 79 patients with systemic non-Hodgkin lymphoma after traditional carmustine, etoposide, cytarabine, and melphalan-conditioned ASCT (BEAM-ASCT)."	7.88	Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. ( Bhatia, A; Chung, HH; DeAngelis, LM; Giralt, SA; Littmann, ER; Maloy, M; Morjaria, SM; Sauter, CS; Scordo, M; Taur, Y, 2018)
"High-dose therapy and autologous stem cell transplantation (ASCT) with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has emerged as an effective postinduction treatment strategy for patients with primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL), but it is associated with considerable toxicity and transplantation-related mortality (TRM) in the modern era."	7.85	A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( Bhatt, V; Dahi, PB; DeAngelis, LM; Giralt, SA; Hsu, M; Matasar, MJ; Moskowitz, CH; Omuro, AM; Sauter, CS; Scordo, M, 2017)
"The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)."	7.77	Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011)
"Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age."	5.16	Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012)
"The combination of high doses of methotrexate (MTX) and cytarabine (araC) is the standard chemotherapy for patients with primary CNS lymphoma (PCNSL)."	5.15	Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. ( Corazzelli, G; Fava, S; Ferreri, AJ; Foppoli, M; Franzin, A; Licata, G; Paolini, R; Politi, LS; Ponzoni, M; Reni, M; Stelitano, C; Zaja, F; Zucca, E, 2011)
"We investigated the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain radiation therapy (WBRT) in patients with newly diagnosed primary central nervous system lymphoma."	5.12	Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol ( Al-Ali, HK; Dölken, G; Haas, A; Helke, K; Herbst, R; Hirt, C; Kiefer, T; Krüger, WH; Lotze, C; Montemurro, M; Niederwieser, D; Schüler, F; Schwenke, M; Theilig, A; Wolf, HH, 2007)
"Thiotepa-based conditioning followed by HSCT may be effective in most CNS lymphoma patients, with a manageable toxicity profile."	4.90	Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma. ( Bredeson, C; Fergusson, D; Kokolo, MB; O'Neill, J; Stewart, D; Tay, J; Tinmouth, AT, 2014)
"A retrospective analysis was performed of 48 consecutive patients who had undergone HDC/ASCT with TBC (thiotepa, busulfan, cyclophosphamide) conditioning for PCNSL (27 patients), secondary CNS lymphoma (SCNSL) (8 patients), or relapsed disease with CNS involvement (13 patients) from July 2006 to December 2017."	3.96	Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. ( Chute, J; de Vos, S; Eradat, HA; Gaut, D; Grotts, J; Kimaiyo, DK; Romero, T; Schiller, G; Timmerman, J; Young, PA, 2020)
"Autologous stem cell transplantation (ASCT) with high-dose thiotepa and busulfan is a treatment option for patients with central nervous system (CNS) lymphoma."	3.96	Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation. ( Aiba, A; Hishizawa, M; Kitano, T; Kondo, T; Nishikori, M; Shimazu, Y; Shindo, T; Takaori-Kondo, A; Wada, F; Watanabe, M, 2020)
"We investigated the incidence of viral, fungal, bacterial, and parasitic infections observed in 57 patients with central nervous system lymphoma after thiotepa, busulfan, and cyclophosphamide-conditioned autologous stem cell transplantation (TBC-ASCT) and 79 patients with systemic non-Hodgkin lymphoma after traditional carmustine, etoposide, cytarabine, and melphalan-conditioned ASCT (BEAM-ASCT)."	3.88	Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. ( Bhatia, A; Chung, HH; DeAngelis, LM; Giralt, SA; Littmann, ER; Maloy, M; Morjaria, SM; Sauter, CS; Scordo, M; Taur, Y, 2018)
"High-dose therapy and autologous stem cell transplantation (ASCT) with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has emerged as an effective postinduction treatment strategy for patients with primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL), but it is associated with considerable toxicity and transplantation-related mortality (TRM) in the modern era."	3.85	A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( Bhatt, V; Dahi, PB; DeAngelis, LM; Giralt, SA; Hsu, M; Matasar, MJ; Moskowitz, CH; Omuro, AM; Sauter, CS; Scordo, M, 2017)
"The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (± R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL)."	3.77	Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. ( Choquet, S; del Rio, MS; Fourme, E; Glaisner, S; Hoang-Xuan, K; Janvier, M; Soussain, C, 2011)
"Current treatments for metastatic breast cancer are not associated with significant survival benefits despite response rates of over 50%."	2.68	High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group. ( Anderson, E; Anderson, T; Cameron, DA; Chetty, U; Craig, J; Dixon, M; Gabra, H; Hawkins, A; Jack, W; Kunkler, I; Lee, L; Leonard, R; Leonard, RC; MacKay, J; Matheson, L; Miller, W; Parker, AC, 1996)
"Relapsed acute myeloid leukemia presenting as an isolated central nervous system myeloid sarcoma (CNS MS) is very rare and generally entails poor outcomes."	1.56	Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series. ( Barbour, M; Bujold, KE; Dandekar, S, 2020)
"Lymphopenia was also a significant prognostic factor for progression-free survival (HR 3."	1.43	A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. ( Cheong, JW; Cho, H; Chung, H; Jang, JE; Kim, JS; Kim, SJ; Kim, Y; Kim, YR; Lee, JY; Min, YH; Park, H, 2016)
"Eleven patients with non-germinomatous germ cell tumors and nine patients with germinomas were enrolled."	1.39	Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study. ( Baek, HJ; Han, JW; Im, HJ; Kang, HJ; Koh, KN; Lee, SH; Park, HJ; Park, KD; Sung, KW, 2013)

Research

Studies (67)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

2-year Overall Survival (OS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (5.97)	18.2507
2000's	12 (17.91)	29.6817
2010's	33 (49.25)	24.3611
2020's	18 (26.87)	2.80

Authors	Studies
Sumangala, S	1
Htwe, T	1
Ansari, Y	1
Martinez-Alvarez, L	1
Schenone, L	1
Houillier, C	3
Tanguy, ML	1
Choquet, S	4
Agbetiafa, K	1
Ghesquières, H	2
Damaj, G	2
Schmitt, A	1
Bouabdallah, K	2
Ahle, G	1
Gressin, R	1
Cornillon, J	1
Houot, R	2
Marolleau, JP	2
Fornecker, LM	1
Chinot, O	1
Peyrade, F	1
Bouabdallah, R	1
Moluçon-Chabrot, C	1
Gyan, E	1
Chauchet, A	1
Casasnovas, O	1
Oberic, L	1
Delwail, V	2
Abraham, J	1
Roland, V	1
Waultier-Rascalou, A	1
Willems, L	1
Morschhauser, F	1
Fabbro, M	1
Ursu, R	1
Thieblemont, C	1
Jardin, F	1
Tempescul, A	1
Malaise, D	1
Touitou, V	2
Nichelli, L	1
Le Garff-Tavernier, M	1
Plessier, A	1
Bourget, P	1
Bonmati, C	1
Wantz-Mézières, S	1
Giordan, Q	1
Dorvaux, V	1
Charron, C	1
Jabeur, W	1
Hoang-Xuan, K	6
Taillandier, L	2
Soussain, C	6
Puckrin, R	1
Chua, N	3
Shafey, M	2
Stewart, DA	5
Ferreri, AJM	4
Cwynarski, K	7
Pulczynski, E	2
Fox, CP	6
Schorb, E	9
Celico, C	1
Falautano, M	1
Nonis, A	1
La Rosée, P	1
Binder, M	3
Fabbri, A	3
Ilariucci, F	3
Krampera, M	2
Roth, A	3
Hemmaway, C	2
Johnson, PW	1
Linton, KM	3
Pukrop, T	2
Gørløv, JS	2
Balzarotti, M	4
Hess, G	2
Keller, U	3
Stilgenbauer, S	3
Panse, J	2
Tucci, A	2
Orsucci, L	2
Pisani, F	2
Zanni, M	1
Krause, SW	2
Schmoll, HJ	2
Hertenstein, B	2
Rummel, M	1
Smith, J	3
Thurner, L	1
Cabras, G	1
Pennese, E	1
Ponzoni, M	4
Deckert, M	3
Politi, LS	3
Finke, J	6
Ferranti, A	1
Cozens, K	1
Burger, E	2
Ielmini, N	1
Cavalli, F	2
Zucca, E	4
Illerhaus, G	10
Wendler, J	1
Valk, E	3
Steinheber, C	1
Fricker, H	3
Isbell, LK	2
Neumaier, S	1
Okosun, J	1
Scherer, F	1
Ihorst, G	4
Nagane, M	1
Kaulen, LD	1
Baehring, JM	1
de Pádua Covas Lage, LA	1
Araújo Soares, V	1
Meneguin, TD	1
Culler, HF	1
Reichert, CO	1
Jacomassi, MD	1
Reis, DGC	1
Zerbini, MCN	1
de Oliveira Costa, R	1
Rocha, V	1
Pereira, J	1
Khwaja, J	1
Kirkwood, AA	1
Steffanoni, S	1
Goradia, H	1
Pospiech, L	1
Fail, T	1
Nicholson, E	1
Fletcher, K	1
Parsons, KE	1
Elmusharaf, N	1
Eccersley, L	1
Eyre, TA	2
Chaganti, S	1
Thakrar, N	1
Kutilina, A	1
Calimeri, T	2
Martinez-Calle, N	2
El-Sharkawi, D	1
Osborne, W	1
Suleman, A	3
Liu, J	3
Hicks, LK	3
Drori, AK	3
Crump, M	3
Kridel, R	3
Prica, A	3
Berinstein, N	3
Arshad, S	1
Fang, X	1
Ahn, KW	1
Kaur, M	1
Scordo, M	3
Sauter, CS	5
Furqan, F	1
Awan, FT	1
Hamadani, M	1
Alderuccio, JP	1
Nayak, L	3
Beca, JM	1
Raza, K	1
Mow, E	1
Keech, J	1
Kouroukis, CT	1
Kasenda, B	5
Linton, K	1
Ninkovic, S	1
Cummin, T	1
Yallop, D	1
De Marco, B	1
Trefz, S	1
Young, PA	1
Gaut, D	1
Kimaiyo, DK	1
Grotts, J	1
Romero, T	1
Chute, J	1
Schiller, G	1
de Vos, S	1
Eradat, HA	1
Timmerman, J	1
Wada, F	1
Nishikori, M	1
Hishizawa, M	1
Watanabe, M	1
Aiba, A	1
Kitano, T	1
Shimazu, Y	1
Shindo, T	1
Kondo, T	2
Takaori-Kondo, A	1
Fries, C	1
Girvin, AR	1
Korones, DN	1
Weintraub, L	1
Fitzpatrick, L	1
Andolina, JR	1
DeFilipp, Z	1
Li, S	2
El-Jawahri, A	1
Armand, P	3
Wang, N	1
Batchelor, TT	2
Chen, YB	3
Fritsch, K	4
Isbell, L	1
Neubauer, A	1
Tzalavras, A	1
Witherall, R	1
Kuittinen, O	1
De-Silva, D	1
Cassoux, N	2
Tamburini, J	1
Morjaria, SM	1
Littmann, ER	1
Bhatia, A	1
Chung, HH	1
Maloy, M	1
DeAngelis, LM	5
Giralt, SA	2
Taur, Y	1
Bujold, KE	1
Dandekar, S	1
Barbour, M	1
Kondo, E	1
Ikeda, T	1
Izutsu, K	1
Chihara, D	1
Shimizu-Koresawa, R	1
Fujii, N	1
Sakai, T	1
Kubo, K	1
Kato, Y	1
Akasaka, T	1
Fukuda, T	1
Ichinohe, T	1
Atsuta, Y	1
Suzumiya, J	1
Suzuki, R	1
Hu, B	1
Sanders, S	1
Larouche, JF	1
Owen, C	2
Hyung, J	1
Hong, JY	1
Yoon, DH	1
Kim, S	1
Park, JS	1
Park, CS	1
Lee, SW	1
Kim, JH	1
Ryu, JS	1
Huh, J	1
Suh, C	1
Baek, HJ	2
Park, HJ	2
Sung, KW	2
Lee, SH	1
Han, JW	1
Koh, KN	1
Im, HJ	1
Kang, HJ	1
Park, KD	2
Kokolo, MB	1
Fergusson, D	1
O'Neill, J	1
Tay, J	1
Tinmouth, AT	1
Stewart, D	1
Bredeson, C	1
Ferreri, AJ	5
Ciceri, F	1
Brandes, AA	2
Montanari, M	2
Spina, M	2
Zaja, F	3
Stelitano, C	3
Bobbio, F	2
Corazzelli, G	3
Baldini, L	2
Reni, M	4
Welch, MR	1
Matasar, MJ	3
Faivre, G	2
Weaver, SA	1
Moskowitz, CH	3
Omuro, AM	3
Batchelor, T	1
Hochberg, E	1
Brezina, M	1
Jones, S	1
Del Rio, C	1
Curtis, M	1
Ballen, KK	1
Barnes, J	1
Chi, AS	1
Dietrich, J	1
Driscoll, J	1
Gertsner, ER	1
Hochberg, F	1
LaCasce, AS	2
McAfee, SL	2
Spitzer, TR	1
Bojic, M	1
Berghoff, AS	1
Troch, M	1
Agis, H	1
Sperr, WR	1
Widhalm, G	1
Wöhrer, A	1
Kalhs, P	1
Preusser, M	1
Rabitsch, W	1
Omuro, A	1
Correa, DD	1
Kaley, TJ	1
Gavrilovic, IT	1
Nolan, C	1
Pentsova, E	1
Grommes, CC	1
Panageas, KS	1
Baser, RE	1
Abrey, LE	2
Oh, DH	1
Street, L	1
van der Weyden, C	1
Prince, HM	1
Lee, MY	1
Kim, HS	2
Lee, JY	2
Lim, SH	1
Kang, ES	1
Ko, YH	1
Kim, SJ	2
Kim, WS	1
Jang, JE	1
Kim, YR	1
Cho, H	1
Chung, H	1
Park, H	1
Kim, Y	1
Cheong, JW	1
Min, YH	1
Kim, JS	1
Mikesch, K	1
Grishina, O	1
Schiff, D	1
Hong, F	1
Alexander, B	1
Torri, V	1
Rosée, PL	1
Ambrosetti, A	1
Ferrari, A	1
Rudà, R	1
Johnson, P	1
Levis, A	1
Egerer, G	1
Lamprecht, M	1
Wolf, HH	2
Hirt, C	2
Hau, P	1
Edinger, M	1
Frickhofen, N	2
Bentz, M	1
Möhle, R	1
Pfreundschuh, M	1
von Baumgarten, L	1
Hader, C	1
Bhatt, V	1
Hsu, M	1
Dahi, PB	1
Grodman, H	1
Wolfe, L	1
Kretschmar, C	1
Rosenfeld, A	1
Kletzel, M	1
Duerst, R	1
Jacobsohn, D	1
Haut, P	1
Weinstein, J	1
Rademaker, A	1
Schaefer, C	1
Evans, L	1
Fouts, M	1
Goldman, S	2
Gilheeney, SW	1
Khakoo, Y	1
Souweidane, M	1
Wolden, S	1
Boulad, F	1
Dunkel, IJ	3
Licata, G	1
Foppoli, M	2
Fava, S	1
Paolini, R	1
Franzin, A	1
del Rio, MS	1
Glaisner, S	1
Fourme, E	2
Janvier, M	1
Cote, GM	1
Hochberg, EP	1
Muzikansky, A	1
Hochberg, FH	1
Drappatz, J	1
Fisher, DC	1
Abramson, JS	1
Alimohamed, N	1
Daly, A	1
Duggan, P	1
Park, ES	1
Won, SC	1
Lim, DH	1
Delgadillo, D	1
Dupriez, B	1
Vargaftig, J	1
Gonzalez, A	1
Leblond, V	2
Cheng, T	1
Forsyth, P	1
Chaudhry, A	1
Morris, D	1
Glück, S	1
Russell, JA	1
Levy, V	2
Yahalom, J	1
Kushner, BH	1
Kramer, K	1
Modak, S	1
Kernan, NA	1
Reich, LM	1
Danis, K	1
Cheung, NK	1
Dell'Oro, S	1
Bernardi, M	1
Tosoni, A	1
Picozzi, P	1
Caligaris Cappio, F	1
Marks, R	1
Guttenberger, R	1
Ostertag, C	1
Derigs, G	1
Feuerhake, F	1
Volk, B	1
Montemurro, M	1
Kiefer, T	1
Schüler, F	1
Al-Ali, HK	1
Herbst, R	1
Haas, A	1
Helke, K	1
Theilig, A	1
Lotze, C	1
Niederwieser, D	1
Schwenke, M	1
Krüger, WH	1
Dölken, G	1
Gill, P	1
Litzow, M	1
Buckner, J	1
Arndt, C	1
Moynihan, T	1
Christianson, T	1
Ansell, S	1
Galanis, E	1
Freilich, RJ	1
Delattre, JY	2
Monjour, A	1
Cameron, DA	1
Craig, J	1
Gabra, H	1
Lee, L	1
MacKay, J	1
Parker, AC	1
Leonard, RC	1
Anderson, E	1
Anderson, T	1
Chetty, U	1
Dixon, M	1
Hawkins, A	1
Jack, W	1
Kunkler, I	1
Leonard, R	1
Matheson, L	1
Miller, W	1
Sandor, V	1
Stark-Vancs, V	1
Pearson, D	1
Nussenblat, R	1
Whitcup, SM	1
Brouwers, P	1
Patronas, N	1
Heiss, J	1
Jaffe, E	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Studio Osservazionale Retrospettivo Multicentrico Sull'Utilizzo di Ibrutinib in Monoterapia o in Associazione a Immunochemioterapia Secondo Schema R-CHOP in Pazienti Adulti Con Diagnosi di PCNSL Ricaduto o Refrattario[NCT05782374]		36 participants (Anticipated)	Observational	2022-08-10	Recruiting
Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612]		50 participants (Anticipated)	Observational	2024-01-01	Not yet recruiting
Phase II Trial of Hihg-Dose Thiotepa, Busulfan, Cyclophosphamide, and Rituximab With Autologous Stem Cell Transplantation for Patients With CNS Involvement by Non-Hodgkin's Lymphoma or Primary CNS Lymphoma[NCT01182415]	Phase 2	30 participants (Actual)	Interventional	2010-06-30	Completed
A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655]	Phase 2	51 participants (Anticipated)	Interventional	2020-09-01	Not yet recruiting
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)[NCT00596154]	Phase 2	33 participants (Actual)	Interventional	2004-12-31	Completed
High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841]	Phase 3	250 participants (Anticipated)	Interventional	2014-07-31	Recruiting
Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Tra[NCT01011920]	Phase 2	126 participants (Actual)	Interventional	2009-11-30	Completed
Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation[NCT00647049]	Phase 2	78 participants (Anticipated)	Interventional	2007-01-31	Recruiting
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]	Phase 2	11 participants (Actual)	Interventional	2010-10-14	Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The percentage of participants alive after two years (NCT01182415)
Timeframe: 2 years

2-year Progression Free Survival (PFS)

Intervention	percentage of participants (Number)
High-dose Chemotherapy With Autologous Stem Cell Transplant	93

The percentage of participants alive and without disease progression at 2 years. Disease progression was judged through clinical impression and MRI imaging. (NCT01182415)
Timeframe: 2 years

Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year

Intervention	percentage of participants (Number)
High-dose Chemotherapy With Autologous Stem Cell Transplant	81

The proportion of patients with central nervous system (CNS) involvement by B-cell Non-Hodgkin's Lymphoma (NHL), relapsed primary central nervous system lymphoma (PCNSL), or relapsed primary intraocular lymphoma (PIOL) who are alive and progression-free at one year. Relapse was defined as per standard PCNSL criteria from clinical and MRI criteria. (NCT01182415)
Timeframe: 3 years

Response Rate

Intervention	Participants (Count of Participants)
High-dose Chemotherapy With Autologous Stem Cell Transplant	28

The number of participants that achieved complete remission following high dose chemotherapy and autologous stem cell transplantation (ASCT). Complete remission is defined as the disappearance of all evidence of disease. Response was judged by MRI assessment. (NCT01182415)
Timeframe: 3 years

Safest Dose of Temozolomide for the DRBEAT Regimen

Intervention	Participants (Count of Participants)
High-dose Chemotherapy With Autologous Stem Cell Transplant	29

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

One-year Progression-free Survival and Overall Survival

Intervention	dose in mg/m^2 (Number)
DRBEAT Regimen	773.25

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

Article	Year
Treatment Options for Recurrent Primary CNS Lymphoma. Current treatment options in oncology, 2022, Volume: 23, Issue:11 Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms	2022
Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology. American Society of Hematology. Education Program, 2017, 12-08, Volume: 2017, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Blood-Brain Barrier; Central Nervous Sys	2017
Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma. Leukemia & lymphoma, 2014, Volume: 55, Issue:12 Topics: Central Nervous System Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Tran	2014
Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review. European journal of haematology, 2015, Volume: 95, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;	2015

Article	Year
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, Volume: 36, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mo	2022
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma. BMC cancer, 2022, Sep-10, Volume: 22, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality	2022
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Alberta; Autografts; Busulfan; Central Nervous System Neoplasms; Dis	2019
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer, 2015, Jan-15, Volume: 121, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols;	2015
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood, 2015, Feb-26, Volume: 125, Issue:9 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap	2015
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood, 2015, Feb-26, Volume: 125, Issue:9 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap	2015
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood, 2015, Feb-26, Volume: 125, Issue:9 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap	2015
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood, 2015, Feb-26, Volume: 125, Issue:9 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap	2015
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix). BMC cancer, 2016, Apr-21, Volume: 16 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop	2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. The Lancet. Haematology, 2016, Volume: 3, Issue:5 Topics: Acute Kidney Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System	2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. The Lancet. Haematology, 2016, Volume: 3, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous	2016
A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors. Journal of neuro-oncology, 2010, Volume: 97, Issue:2 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neop	2010
Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatric blood & cancer, 2010, Volume: 54, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neop	2010
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. The oncologist, 2011, Volume: 16, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combi	2011
Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. Leukemia & lymphoma, 2012, Volume: 53, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Central Nervo	2012
Tandem high-dose chemotherapy and autologous stem cell transplantation in young children with atypical teratoid/rhabdoid tumor of the central nervous system. Journal of Korean medical science, 2012, Volume: 27, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child	2012
Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica, 2012, Volume: 97, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla	2012
Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology, 2005, Jan-11, Volume: 64, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System Neoplasms	2005
Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. Bone marrow transplantation, 2006, Volume: 37, Issue:3 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cent	2006
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology, 2006, May-09, Volume: 66, Issue:9 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop	2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;	2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;	2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;	2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms;	2006
Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous S	2007
Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology, 1996, Volume: 46, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cent	1996
High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group. British journal of cancer, 1996, Volume: 74, Issue:12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neop	1996
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytar	1998
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-01, Volume: 19, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; C	2001

Article	Year
Primary leptomeningeal lymphoma masquerading as infectious tubercular meningitis. BMJ case reports, 2021, Sep-13, Volume: 14, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma,	2021
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network. Bone marrow transplantation, 2022, Volume: 57, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Centra	2022
Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant. Leukemia & lymphoma, 2022, Volume: 63, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous S	2022
[Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:9 Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Central N	2022
The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings? Radiation oncology (London, England), 2022, Oct-22, Volume: 17, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System; Central Nervous Syste	2022
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. Haematologica, 2023, 03-01, Volume: 108, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl	2023
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience. Haematologica, 2023, 04-01, Volume: 108, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl	2023
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience. Haematologica, 2023, 04-01, Volume: 108, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl	2023
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience. Haematologica, 2023, 04-01, Volume: 108, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl	2023
Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience. Haematologica, 2023, 04-01, Volume: 108, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neopl	2023
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning. Bone marrow transplantation, 2023, Volume: 58, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Central Nervous Syste	2023
How I treat secondary CNS involvement by aggressive lymphomas. Blood, 2023, Nov-23, Volume: 142, Issue:21 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lym	2023
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma. Leukemia & lymphoma, 2020, Volume: 61, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Central Nervous System; Central Nervous Syst	2020
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice. British journal of haematology, 2020, Volume: 189, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst	2020
Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Cy	2020
Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation. International journal of hematology, 2020, Volume: 112, Issue:5 Topics: Adult; Aged; Busulfan; Central Nervous System Neoplasms; Female; Hematopoietic Stem Cell Transplanta	2020
Myeloablative Carboplatin and Thiotepa With Autologous Stem Cell Rescue for Nonmedulloblastoma High-risk CNS Tumors in Young Children. Journal of pediatric hematology/oncology, 2021, Nov-01, Volume: 43, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous System Neoplasms; Child	2021
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer, 2017, Aug-15, Volume: 123, Issue:16 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Busulfan; Central	2017
High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone marrow transplantation, 2017, Volume: 52, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Combin	2017
Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:9 Topics: Busulfan; Central Nervous System Neoplasms; Cyclophosphamide; Female; Humans; Lymphoma; Male; Middle	2018
Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series. Journal of pediatric hematology/oncology, 2020, Volume: 42, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child, Preschool;	2020
High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Femal	2019
A Tale of Two Eras: The Story of Autologous Stem Cell Transplantation with and without Thiotepa for Primary Central Nervous System Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:5 Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Hematopoietic Stem Cell Transpl	2019
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. Annals of hematology, 2019, Volume: 98, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System N	2019
Myeloablative chemotherapy and autologous stem cell transplantation in patients with relapsed or progressed central nervous system germ cell tumors: results of Korean Society of Pediatric Neuro-Oncology (KSPNO) S-053 study. Journal of neuro-oncology, 2013, Volume: 114, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous Syst	2013
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. Neurology, 2014, Apr-15, Volume: 82, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality	2014
Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Leukemia & lymphoma, 2015, Volume: 56, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla	2015
Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. Leukemia & lymphoma, 2016, Volume: 57, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; Combined	2016
High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from "orphan drug" to a standard-of-care? Leukemia & lymphoma, 2016, Volume: 57, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lymphoma;	2016
Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement. International journal of hematology, 2015, Volume: 102, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplas	2015
A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. European journal of cancer (Oxford, England : 1990), 2016, Volume: 57 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla	2016
Defining optimal initial therapy for primary CNS lymphoma. The Lancet. Haematology, 2016, Volume: 3, Issue:5 Topics: Central Nervous System Neoplasms; Cytarabine; Humans; Methotrexate; Rituximab; Thiotepa	2016
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla	2017
Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue. Pediatric blood & cancer, 2009, Volume: 53, Issue:1 Topics: Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nerv	2009
Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma. Journal of neuro-oncology, 2011, Volume: 105, Issue:2 Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combin	2011
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla	2012
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop	2012
High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone marrow transplantation, 2003, Volume: 31, Issue:8 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Busulfan;	2003
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma]. Bulletin du cancer, 2004, Volume: 91, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla	2004
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer, 2008, Apr-15, Volume: 112, Issue:8 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic;	2008
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors. Bone marrow transplantation, 2000, Volume: 26, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm	2000
Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue. Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:2 Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Ph	2002
Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases. Anti-cancer drugs, 1990, Volume: 1, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Axons; Central Nervous System Neo	1990

thiotepa and Central Nervous System Neoplasm